NCT06746480View on ClinicalTrials.gov

Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 19, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

December 1, 2025

Conditions
Advanced Intrahepatic Cholangiocarcinoma
Interventions
DRUG

Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))

Intratumoral injection only. The dosing date is Days 1 through 3.

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

CNBG-Virogin Biotech (Shanghai) Ltd.

INDUSTRY